WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H597985
CAS#: 106362-32-7
Description: Peptide T is a segment corresponding to residues 185-192 of gp120, the coat protein of HIV.
Hodoodo Cat#: H597985
Name: Peptide T
CAS#: 106362-32-7
Chemical Formula: C35H55N9O16
Exact Mass: 857.38
Molecular Weight: 857.870
Elemental Analysis: C, 49.00; H, 6.46; N, 14.69; O, 29.84
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Peptide T;
IUPAC/Chemical Name: L-alanyl-L-seryl-L-threonyl-L-threonyl-L-threonyl-L-asparaginyl-L-tyrosyl-L-threonine
InChi Key: IWHCAJPPWOMXNW-LYKMMFCUSA-N
InChi Code: InChI=1S/C35H55N9O16/c1-13(36)28(52)40-22(12-45)31(55)41-25(15(3)47)33(57)43-26(16(4)48)34(58)42-24(14(2)46)32(56)39-21(11-23(37)51)29(53)38-20(10-18-6-8-19(50)9-7-18)30(54)44-27(17(5)49)35(59)60/h6-9,13-17,20-22,24-27,45-50H,10-12,36H2,1-5H3,(H2,37,51)(H,38,53)(H,39,56)(H,40,52)(H,41,55)(H,42,58)(H,43,57)(H,44,54)(H,59,60)/t13-,14+,15+,16+,17+,20-,21-,22-,24-,25-,26-,27-/m0/s1
SMILES Code: C[C@@H](O)[C@@H](C(O)=O)NC([C@H](CC1=CC=C(O)C=C1)NC([C@H](CC(N)=O)NC([C@H]([C@H](O)C)NC([C@H]([C@H](O)C)NC([C@H]([C@H](O)C)NC([C@H](CO)NC([C@H](C)N)=O)=O)=O)=O)=O)=O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 857.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Gu R, He Y, Han S, Yuan S, An Y, Meng Z, Zhu X, Gan H, Wu Z, Li J, Zheng Y, Zhang L, Gao L, Dou G. Pharmacokinetics and bioavailability of tuftsin-derived T peptide, a promising antitumor agent, in beagles. Drug Metab Pharmacokinet. 2016 Feb;31(1):51-56. doi: 10.1016/j.dmpk.2015.08.005. Epub 2015 Aug 28. PubMed PMID: 26775850.
2: D'ursi A, Caliendo G, Perissutti E, Santagada V, Severino B, Albrizio S, Bifulco G, Spisani S, Temussi PA. Conformation-activity relationship of peptide T and new pseudocyclic hexapeptide analogs. J Pept Sci. 2007 Jun;13(6):413-21. PubMed PMID: 17486694.
3: Simpson DM, Dorfman D, Olney RK, McKinley G, Dobkin J, So Y, Berger J, Ferdon MB, Friedman B. Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group. Neurology. 1996 Nov;47(5):1254-9. PubMed PMID: 8909439.
4: Ruff MR, Polianova M, Yang QE, Leoung GS, Ruscetti FW, Pert CB. Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors. Curr HIV Res. 2003 Jan;1(1):51-67. Review. PubMed PMID: 15043212.
5: Ruff MR, Smith C, Kingan T, Jaffe H, Heseltine P, Gill MA, Mayer K, Pert CB, Bridge TP. Pharmacokinetics of peptide T in patients with acquired immunodeficiency syndrome (AIDS). Prog Neuropsychopharmacol Biol Psychiatry. 1991;15(6):791-801. PubMed PMID: 1763193.
6: Farber EM, Cohen EN, Trozak DJ, Wilkinson DI. Peptide T improves psoriasis when infused into lesions in nanogram amounts. J Am Acad Dermatol. 1991 Oct;25(4):658-64. PubMed PMID: 1791224.
7: Raychaudhuri SP, Farber EM, Raychaudhuri SK. Immunomodulatory effects of peptide T on Th 1/Th 2 cytokines. Int J Immunopharmacol. 1999 Sep;21(9):609-15. PubMed PMID: 10501630.
8: Heseltine PN, Goodkin K, Atkinson JH, Vitiello B, Rochon J, Heaton RK, Eaton EM, Wilkie FL, Sobel E, Brown SJ, Feaster D, Schneider L, Goldschmidts WL, Stover ES. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol. 1998 Jan;55(1):41-51. PubMed PMID: 9443710.
9: Johansson O, Hilliges M, Talme T, Marcusson JA, Wetterberg L. Somatostatin immunoreactive cells in lesional psoriatic human skin during peptide T treatment. Acta Derm Venereol. 1994 Mar;74(2):106-9. PubMed PMID: 7911613.
10: Bagger MA, Nielsen HW, Bechgaard E. Nasal bioavailability of peptide T in rabbits: absorption enhancement by sodium glycocholate and glycofurol. Eur J Pharm Sci. 2001 Aug;14(1):69-74. PubMed PMID: 11457652.
11: Redwine LS, Pert CB, Rone JD, Nixon R, Vance M, Sandler B, Lumpkin MD, Dieter DJ, Ruff MR. Peptide T blocks GP120/CCR5 chemokine receptor-mediated chemotaxis. Clin Immunol. 1999 Nov;93(2):124-31. PubMed PMID: 10527688.
12: Centeno NB, Perez JJ. A proposed bioactive conformation of peptide T. J Comput Aided Mol Des. 1998 Jan;12(1):7-14. PubMed PMID: 9570085.
13: Sáez-Torres I, Espejo C, Pérez JJ, Acarín N, Montalban X, Martínez-Cáceres EM. Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats. Clin Exp Immunol. 2000 Jul;121(1):151-6. PubMed PMID: 10886253; PubMed Central PMCID: PMC1905669.
14: Yuwiler A, Wetterberg L. Peptide T does not affect induction of pineal N-acetyltransferase by vasoactive intestinal peptide. Regul Pept. 1989 Apr;25(1):69-73. PubMed PMID: 2717784.
15: Su SF, Amidon GL. Investigation into the intestinal metabolism of [D-Ala1] peptide T amide: implication for oral drug delivery. Biochim Biophys Acta. 1995 Aug 17;1245(1):62-8. PubMed PMID: 7654767.
16: De Dios AC, Sears DN, Tycko R. NMR studies of peptide T, an inhibitor of HIV infectivity, in an aqueous environment. J Pept Sci. 2004 Oct;10(10):622-30. PubMed PMID: 15526711.
17: Metwally E, Befus AD, Davison JS, Mathison R. Probing for submandibular gland peptide-T receptors on leukocytes with biotinylated-Lys-[Gly](6)-SGP-T. Biochim Biophys Acta. 2002 Dec 16;1593(1):37-44. PubMed PMID: 12431782.
18: Ruff MR, Melendez-Guerrero LM, Yang QE, Ho WZ, Mikovits JW, Pert CB, Ruscetti FA. Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res. 2001 Oct;52(1):63-75. PubMed PMID: 11530189.
19: Marastoni M, Salvadori S, Balboni G, Spisani S, Gavioli R, Traniello S, Tomatis R. Synthesis, metabolic stability and chemotactic activity of peptide T and its analogues. Int J Pept Protein Res. 1990 Feb;35(2):81-8. PubMed PMID: 2323889.
20: Liapi C, Takahashi N, Raynaud F, Evain-Brion D, Anderson WB. Effects of [D-Ala1] peptide T-NH2 and HIV envelope glycoprotein gp120 on cyclic AMP dependent protein kinases in normal and psoriatic human fibroblasts. J Invest Dermatol. 1998 Apr;110(4):332-7. PubMed PMID: 9540970.
